Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease

BACKGROUND: Patients with pre-existing autoimmune disease (AD) have been largely excluded from clinical trials of immune checkpoint inhibitors (ICI), so data on safety of ICIs among patients with pre-existing AD are relatively limited. There is a need for deeper understanding of the type and managem...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Transl Med
Hlavní autoři: Alexander, Swetha, Swami, Umang, Kaur, Aneet, Gao, Yubo, Fatima, Munazza, Ginn, Meredith M., Stein, Jill E., Grivas, Petros, Zakharia, Yousef, Singh, Namrata
Médium: Artigo
Jazyk:Inglês
Vydáno: AME Publishing Company 2021
Témata:
Original Article on Cancer Immunotherapy: Recent Advances and Challenges
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8267316/
https://ncbi.nlm.nih.gov/pubmed/34277833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm-20-8124
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky